[go: up one dir, main page]

MX2009003090A - Genes novedosos relacionados con ciclasa de glutaminilo. - Google Patents

Genes novedosos relacionados con ciclasa de glutaminilo.

Info

Publication number
MX2009003090A
MX2009003090A MX2009003090A MX2009003090A MX2009003090A MX 2009003090 A MX2009003090 A MX 2009003090A MX 2009003090 A MX2009003090 A MX 2009003090A MX 2009003090 A MX2009003090 A MX 2009003090A MX 2009003090 A MX2009003090 A MX 2009003090A
Authority
MX
Mexico
Prior art keywords
glutaminyl cyclase
isoenzymes
glutaminyl
cyclase
genes related
Prior art date
Application number
MX2009003090A
Other languages
English (en)
Inventor
Hans-Ulrich Demuth
Stephen Schilling
Holger Cynis
Jens-Ulrich Rahfeld
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of MX2009003090A publication Critical patent/MX2009003090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)

Abstract

La presente invención se refiere a una proteína tipo ciclotransferasa de péptido-glutaminilo novedosas QPCTLs, que son isoenzimas de ciclasa de glutaminilo (QC, EC 2.3.3.5), y a ácidos nucleicos aislados que codifican estas isoenzimas, las cuales todas son útiles para el descubrimiento de nuevos agentes terapéuticos, para medir la actividad de ciclasa, y para determinar la actividad inhibidora de los compuestos contra estas isoenzimas de ciclasa de glutaminilo.
MX2009003090A 2006-09-21 2007-09-21 Genes novedosos relacionados con ciclasa de glutaminilo. MX2009003090A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84624406P 2006-09-21 2006-09-21
US94778007P 2007-07-03 2007-07-03
PCT/EP2007/060013 WO2008034891A2 (en) 2006-09-21 2007-09-21 Novel genes related to glutaminyl cyclase

Publications (1)

Publication Number Publication Date
MX2009003090A true MX2009003090A (es) 2009-04-02

Family

ID=38779576

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003090A MX2009003090A (es) 2006-09-21 2007-09-21 Genes novedosos relacionados con ciclasa de glutaminilo.

Country Status (12)

Country Link
US (3) US20080249083A1 (es)
EP (2) EP2581449B1 (es)
JP (1) JP2010504088A (es)
KR (1) KR101432848B1 (es)
AU (1) AU2007298929B2 (es)
BR (1) BRPI0718507A2 (es)
CA (1) CA2663635A1 (es)
EA (1) EA016584B1 (es)
IL (2) IL197090A (es)
MX (1) MX2009003090A (es)
NZ (2) NZ575727A (es)
WO (1) WO2008034891A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572274A (en) * 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US20080249083A1 (en) * 2006-09-21 2008-10-09 Probiodrug Ag Novel genes related to glutaminyl cyclase
US9277737B2 (en) 2006-09-21 2016-03-08 Probiodrug Ag Mouse models carrying a knock-out mutation of the QPCTL-gene
US8889709B2 (en) 2006-09-21 2014-11-18 Probiodrug Ag Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions
WO2008055945A1 (en) * 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US7741354B2 (en) * 2006-11-09 2010-06-22 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8420684B2 (en) * 2006-11-09 2013-04-16 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2091948B1 (en) * 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
HRP20110651T1 (hr) * 2007-01-19 2011-10-31 Probiodrug Ag Modeli pretraživanja in vivo radi liječenja alzheimerove bolesti i drugih poremećaja povezanih s qpct
US7803810B2 (en) * 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
US8772508B2 (en) * 2007-04-18 2014-07-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9512082B2 (en) * 2007-04-18 2016-12-06 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008128982A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
US9656991B2 (en) * 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8202897B2 (en) * 2007-04-18 2012-06-19 Probiodrug Ag Inhibitors of glutaminyl cyclases
DK2160380T3 (da) * 2007-04-18 2014-06-30 Probiodrug Ag Cyano-guanidin derivater som glutaminyl cyclase inhibitorer
JP5676249B2 (ja) * 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
EP2195336B1 (en) * 2007-09-12 2015-01-21 Probiodrug AG Transgenic mice
EP2238252B1 (en) * 2008-01-14 2013-07-31 Probiodrug AG Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
NZ590658A (en) * 2008-07-31 2012-07-27 Probiodrug Ag Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
EP2344158B1 (en) * 2008-09-04 2017-12-27 Probiodrug AG Use of isoqc inhibitors
EP2344157B1 (en) * 2008-09-04 2016-05-25 Probiodrug AG Novel inhibitors
EP2432314B1 (en) * 2009-05-19 2017-12-20 Probiodrug AG Mouse models carrying a knock-out mutation of the qpctl-gene
SG182615A1 (en) * 2010-02-18 2012-08-30 Probiodrug Ag Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
US8409837B2 (en) 2010-08-19 2013-04-02 Probiodrug Ag Crystal structure of glutaminyl cyclase
WO2012028706A1 (en) 2010-09-02 2012-03-08 Probiodrug Ag IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
US8741614B2 (en) 2010-11-02 2014-06-03 Probiodrug Ag Crystal structure of isoglutaminyl cyclase
EP2874997A4 (en) 2012-07-19 2016-01-06 Univ Drexel NEW SIGMA RECEPTOR LIGANDS AND METHOD FOR REGULATING CELLULAR PROTEIN HOMEOSTASIS THEREWITH
WO2017079547A2 (en) * 2015-11-04 2017-05-11 The Scripps Research Institute Compositions and methods for treating cystic fibrosis
PL3658141T3 (pl) * 2017-07-24 2023-06-12 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases
GB201918108D0 (en) * 2019-12-10 2020-01-22 Vib Vzw Improved aminopeptiadases for single molecule peptide sequencing
WO2025224169A1 (en) 2024-04-23 2025-10-30 Vivoryon Therapeutics N.V. Dose regimens for the glutaminyl cyclase inhibitor varoglutamstat
WO2025224179A1 (en) 2024-04-23 2025-10-30 Vivoryon Therapeutics N.V. Glutaminyl cyclase inhbitors for use in the treatment of kidney disease

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IT1183575B (it) 1985-05-08 1987-10-22 Eurand Spa Formulazione deodorando ad effetto modulante sulla trfaspirazione
DD293584A5 (de) 1990-03-23 1991-09-05 Adw,Zi Fuer Organische Chemie,De Verfahren zur herstellung von neuen 3,5,5-trisubstituierten 1-(benzimidazol-2-yl)-imidazolidin-2,4-dionen bzw. -4-on-2-thionen
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6247293B1 (en) * 1998-11-03 2001-06-19 Klockner Bartelt, Inc. Modular packaging machine with web tension control
FR2796945B1 (fr) 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
WO2001053331A2 (en) 2000-01-24 2001-07-26 Adherex Technologies, Inc. Peptidomimetic modulators of cell adhesion
FR2808711B1 (fr) * 2000-05-10 2002-08-09 Poudres & Explosifs Ste Nale Procede de fabrication d'elements composites etain-tungstene de faible epaisseur
EP1388107A1 (en) * 2001-05-11 2004-02-11 Swisscom Mobile AG Method for transmitting an anonymous request from a consumer to a content or service provider through a telecommunication network
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
KR100474689B1 (ko) * 2001-08-30 2005-03-08 삼성전자주식회사 이동통신 시스템에서 소프트 핸드오프 도중의 전력제어 방법
WO2003045321A2 (en) * 2001-11-26 2003-06-05 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7677859B2 (en) 2002-07-22 2010-03-16 Brooks Automation, Inc. Substrate loading and uploading station with buffer
GB0220501D0 (en) * 2002-09-04 2002-10-09 Hall Geoffrey W Push 22
US20040098591A1 (en) * 2002-11-15 2004-05-20 Fahrny James W. Secure hardware device authentication method
US6851324B2 (en) * 2002-12-16 2005-02-08 Delphi Technologies, Inc. Non-contacting compliant torque sensor
US7371871B2 (en) * 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
MXPA05011861A (es) * 2003-05-05 2006-02-17 Probiodrug Ag Uso de efectores de ciclasas de glutamato y glutaminil.
NZ572274A (en) * 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US8338120B2 (en) * 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
US7192995B2 (en) * 2003-10-03 2007-03-20 Virginia Commonwealth University Homogenous compositions of polymers and crystalline solids or cross-linking agents and methods of making the same
EA010108B1 (ru) * 2003-10-15 2008-06-30 Пробиодруг Аг Применение эффекторов глутаминил- и глутаматциклаз
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7667044B2 (en) * 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
CA2544573A1 (en) * 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20080027033A1 (en) * 2003-11-19 2008-01-31 Acrux Dds Pty Ltd Method and Composition for Treatment of Cutaneous Lesions
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
AU2004321982B2 (en) * 2004-07-01 2009-10-29 Micro Motion, Inc. Split balance weights for eliminating density effect on flow
US7663268B2 (en) * 2006-08-30 2010-02-16 The Regents of the University of Cailfornia Converters for high power applications
US20080249083A1 (en) 2006-09-21 2008-10-09 Probiodrug Ag Novel genes related to glutaminyl cyclase
JP5456479B2 (ja) 2006-11-09 2014-03-26 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
JP5676249B2 (ja) * 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体

Also Published As

Publication number Publication date
CA2663635A1 (en) 2008-03-27
IL197090A0 (en) 2011-08-01
KR20090059163A (ko) 2009-06-10
JP2010504088A (ja) 2010-02-12
EP2082041B1 (en) 2018-03-14
AU2007298929B2 (en) 2012-09-27
US8129160B2 (en) 2012-03-06
WO2008034891A3 (en) 2008-05-08
IL197090A (en) 2016-03-31
US20100009337A1 (en) 2010-01-14
US8647834B2 (en) 2014-02-11
IL214820A (en) 2016-06-30
HK1136603A1 (zh) 2010-07-02
US20080249083A1 (en) 2008-10-09
BRPI0718507A2 (pt) 2013-11-12
NZ575727A (en) 2011-12-22
EP2581449B1 (en) 2016-09-14
US20120183974A1 (en) 2012-07-19
EP2581449A3 (en) 2013-07-31
EP2581449A2 (en) 2013-04-17
IL214820A0 (en) 2011-09-27
KR101432848B1 (ko) 2014-08-27
NZ590631A (en) 2011-12-22
EA200900404A1 (ru) 2009-10-30
WO2008034891A2 (en) 2008-03-27
EP2082041A2 (en) 2009-07-29
EA016584B1 (ru) 2012-06-29
AU2007298929A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
MX2009003090A (es) Genes novedosos relacionados con ciclasa de glutaminilo.
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
NO20080067L (no) Polypeptider som har antimikrobeaktivitet og polynukleotider som koder for disse
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
DK1597391T3 (da) Anvendelse af intron-RNA til måling af genekspression
EA201201640A1 (ru) Способы определения устойчивости рака к ингибиторам гистондеацетилазы
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
WO2011138751A3 (en) Heterocyclic derivatives as alk inhibitors
PT2491942E (pt) Utilização de inibidores peptídicos aos quais as células são permeáveis da via de transdução de sinal de jnk para o tratamento de várias doenças cardiovasculares
WO2004076639A8 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
MX2012002272A (es) Dominios cataliticos de lisil oxidasa y loxl2.
MA29340B1 (fr) Nouveaux composes
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
WO2009086215A3 (en) Pathway analysis of cell culture phenotypes and uses thereof
WO2008104979A3 (en) Nuclear targeting sequences
WO2008054514A3 (en) Differential expression profiling analysis of cell culture phenotypes and the uses thereof
TW200745047A (en) Heterocyclic compounds
EP2647647A3 (en) Thiopeptide precursor protein, gene encoding it and uses thereof
MX2008001538A (es) Aril piridinas y metodos para su uso.
NO20070640L (no) Forbedrede aprotininvananter
ATE439361T1 (de) 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
IL205289A0 (en) Amino 1, 2, 4 - triazole derivatives as modulators of mglur5
WO2008148932A3 (en) Glycosylasparaginase for treatment of cancers or inflammatory diseases
WO2008061239A3 (en) Compositions and methods for detecting noonan syndrome
WO2007041513A3 (en) Conserved membrane activator of calcineurin (cmac), a novel therapeutic protein and target

Legal Events

Date Code Title Description
FG Grant or registration